Alpha-GPC

Also called L-alpha-glycerylphosphorylcholine, choline alfoscerate, choline alphoscerate, glycerophosphocholine, A-GPC

By Kymata Labs EditorialMedical review pendingLast reviewed October 11, 2026 · What changed

Kymata Health may earn a commission from links on separate product pages. This page contains no product links. Educational reference, not medical advice.

Summary

Alpha-GPC is a choline source. Trials in Alzheimer-type dementia and mild cognitive impairment found better cognitive scores than placebo (grade B), and small studies in healthy men reported short-term gains in force and attention (grade D). A Korean cohort of 12 million adults linked prescribed alpha-GPC to higher 10-year stroke risk.

Top graded outcomes:B evidence grade Cognitive scores in mild to moderate Alzheimer-type dementiaB evidence grade Cognitive scores in mild cognitive impairmentD evidence grade Lower-body force production

Key facts

What it is
A choline-containing phospholipid; marketed as a medicine since 1985 in some countries and as a supplement elsewhere[4]
Best-studied outcome
Cognitive scores in Alzheimer-type dementia and mild cognitive impairment (grade B)[2][3]
Studied doses
600–1,200 mg/day in cognition trials; 315–630 mg single doses in healthy men[2][3][6]
Safety signal
Observational: users had about 1.4-fold higher adjusted 10-year stroke risk in a Korean national cohort[7]
Evidence base
4 graded human outcomes on this page
Last reviewed
October 11, 2026

How it works

ProposedAlpha-GPC supplies choline, which the body uses to make acetylcholine and phospholipids. Gut bacteria can turn choline into TMAO, a metabolite studied as a possible cardiovascular risk factor; mouse work links alpha-GPC to atherosclerosis through this route.[1][8]

What the human research says

Human trials only, one row per outcome. The form column shows what each trial actually tested. Grades follow our evidence-grading policy.

At a glance: strongest evidence per outcome

Evidence at a glance: strongest human evidence per outcome
OutcomeGradeEffectStrongest evidenceRows
CognitionGrade BImprovedRCT · n = 261 · 2003Form tested: Choline alfoscerate capsules3 rowsIncludes this form
ExerciseGrade DImprovedCrossover RCT · n = 13 · 2015Form tested: Alpha-GPC1 rowIncludes this form

Every graded row

Outcome
Grade
Form tested
Sort

Showing 4 of 4 outcomes. Human trials only.

OutcomeEffectGradeBest evidencePMID
Cognitive scores in mild to moderate Alzheimer-type dementiaImprovedGrade B

RCT · n = 261 · 2003

Adults aged 60–80 with mild to moderate Alzheimer-type dementia

Form: Choline alfoscerate capsules · Dose: 400 mg three times daily (1,200 mg/day) · Duration: 180 days

ADAS-Cog, MMSE and global impression scores improved versus placebo at 90 and 180 days.

12637119 (opens PubMed)Source [2]
Cognitive scores in mild cognitive impairmentImprovedGrade B

RCT · n = 100 · 2024

Adults with mild cognitive impairment

Form: Alpha-GPC soft capsule · Dose: 600 mg/day · Duration: 12 weeks

ADAS-Cog improved by 2.34 points more than placebo; adverse events did not differ between groups.

39300341 (opens PubMed)Source [3]
Attention test (Stroop) after one doseImprovedGrade D

Crossover RCT · n = 20 · 2024

Resistance-trained men

Form: Alpha-GPC (GeniusPure) · Dose: 315 mg or 630 mg single dose · Duration: Single dose

Stroop scores improved more after both doses than after placebo 60 minutes after intake.

39683633 (opens PubMed)Source [6]
Lower-body force productionImprovedGrade D

Crossover RCT · n = 13 · 2015

College-aged men

Form: Alpha-GPC · Dose: 600 mg/day · Duration: 6 days

Isometric mid-thigh pull peak force rose more than with placebo; upper-body force did not differ.

26582972 (opens PubMed)Source [5]

Forms

FormElemental %Absorption (human data)GI toleranceStudied for
Alpha-GPC (choline alfoscerate)Varies[10]About 40% choline by weight (choline 104.2 g/mol ÷ alpha-GPC 257.2 g/mol); labels list the compound weightPlasma choline exposure was similar to other choline supplements in a small crossover study, and TMAO rose quickly (n=6).[9]Adverse events did not differ from placebo in the 12-week MCI trial.[3]Cognition trials in dementia and MCI; short exercise studies

Studied doses

Doses studied in human trials ranged from single doses of 315–630 mg in healthy men to 600 mg/day for 12 weeks in mild cognitive impairment and 1,200 mg/day (400 mg three times daily) for 180 days in Alzheimer-type dementia.[6][3][2]

Intake reference: Alpha-GPC has no intake reference of its own. For total choline, adults have an Adequate Intake of 425 mg/day (women) and 550 mg/day (men) and a UL of 3,500 mg/day.[1] NIH ODS fact sheet (updated June 2, 2022).

These are amounts used in research, not personal advice. Your clinician or pharmacist can say what fits you.

Interactions

Published interactions only: each row cites a source. No row means none was found in our sources, not that a combination is safe.

Other supplements

  • Other choline sourcesNIH fact sheete.g. choline bitartrate, citicoline, lecithinCholine from all sources counts toward the 3,500 mg/day upper limit, set because high intakes cause fishy body odour, sweating and low blood pressure.[1]

Who should be careful

Stroke risk factors
In a South Korean national cohort, prescribed alpha-GPC was associated with higher 10-year stroke risk in a dose-response pattern; this is observational and does not prove cause.[7]
Pregnancy and breastfeeding
Trials cited here did not enrol pregnant or breastfeeding people; choline needs in pregnancy are covered on the choline page.[1]

Talk to your pharmacist or clinician before starting a supplement, especially if you take prescription medicines.

Frequently asked questions

Does alpha-GPC improve memory in healthy people?

Evidence in healthy adults is limited to small, short studies. The stronger trials enrolled people with dementia or mild cognitive impairment.[6][2]

How much choline is in alpha-GPC?

About 40% of alpha-GPC by weight is choline, so 600 mg supplies roughly 240 mg of choline.[10]

Is alpha-GPC linked to stroke?

A 2021 cohort of 12 million Korean adults found higher stroke risk among people prescribed alpha-GPC. It was observational, so it shows an association, not proof.[7]

Alpha-GPC or citicoline?

Both supply choline. No head-to-head trial in healthy adults is cited here; each has its own trials in different groups.[3]

Sources

  1. [1]Choline: Fact Sheet for Health Professionals. NIH Office of Dietary Supplements, 2022. fact-sheet
  2. [2]Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.. Clin Ther, 2003. RCT PMID 12637119
  3. [3]Efficacy and safety of choline alphoscerate for amnestic mild cognitive impairment: a randomized double-blind placebo-controlled trial.. BMC Geriatr, 2024. RCT PMID 39300341
  4. [4]Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis.. J Alzheimers Dis, 2023. meta-analysis PMID 36683513
  5. [5]The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength.. J Int Soc Sports Nutr, 2015. crossover-RCT PMID 26582972
  6. [6]Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men.. Nutrients, 2024. crossover-RCT PMID 39683633
  7. [7]Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years.. JAMA Netw Open, 2021. observational PMID 34817582
  8. [8]The Nutritional Supplement L-Alpha Glycerylphosphorylcholine Promotes Atherosclerosis.. Int J Mol Sci, 2021. animal-study PMID 34948275
  9. [9]Differential metabolism of choline supplements in adult volunteers.. Eur J Nutr, 2022. PK-study PMID 34287673
  10. [10]Glycerophosphocholine (compound summary). PubChem, NIH National Library of Medicine, 2026. database

What changed

  1. October 11, 2026 · all · new page (encyclopedia expansion, A–L)First draft. Every PMID checked against NCBI E-utilities (title, journal and year taken from the PubMed record) and each evidence row written from its PubMed abstract.Writer: Kymata Labs Editorial · No credentialed reviewer yet

How we write, grade and correct these pages: editorial and evidence policy.

Supplement & Nutrient Encyclopedia. Educational information only; it is not medical advice and does not replace a clinician. Dietary supplements are not intended to diagnose, treat, cure or prevent any disease. Statements about supplements have not been evaluated by the FDA.

Supplements and vitamins: every page →Supplement & Nutrient Encyclopedia →Browse all topics →

Evidence-graded supplement stacks →